XSHE
300453
Market cap707mUSD
Jul 09, Last price
9.19CNY
1D
-1.50%
1Q
-7.45%
Jan 2017
26.77%
IPO
195.71%
Name
Jiangxi Sanxin Medtec Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Nanchang, China, in 1997, Jiangxi Sanxin Medtec Co., Ltd. is a medical technology company dedicated to the research, development, manufacturing, sales, and servicing of medical devices. The company operates both domestically and internationally, offering a wide array of products across several key therapeutic categories: Renal Dialysis and Blood Purification: This segment includes advanced centralized dialysate supply systems, hemodialysis water preparation units, and hemodialysis machines. It also provides a variety of consumables such as specialized nursing kits, central venous catheter packs, arteriovenous spikes, HDF accessory tubing, dialysate filters, hemodialysis powders and concentrates, hollow fiber hemodialyzers, sterile blood circuits, and tubing sets for hemodialysis. Infusion and Transfusion Equipment: The company supplies various infusion and transfusion sets, including light-resistant, TPE precise filter, and auto-stop fluid precise filter types, alongside standard transfusion sets, catheter infusion sets, and precise filter light-resistant options. Injection Devices: Its portfolio encompasses diverse syringes, such as insulin, dispenser, sterile, auto-disable, and fixed-dose immunization syringes. This category also features hypodermic needles, innovative needleless injection systems, and pneumatic syringes. Intravenous Catheterization Products: Offerings include various indwelling catheters like straight, Y-type, and closed IV catheters, positive pressure IV catheters, central venous catheter kits, extension tubes with three-way valves, and heparin caps. General Medical Supplies: Additional products include blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, blood containers, medical-grade surgical masks, disinfectants, and alcohol pads.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||